The Company submitted a listing application to the NMPA in respect of major product, Olorigliflozin Capsules, a Category 1 new drug, and the application was accepted.
The Company obtained clinical trial approval for HEC169584, which is first new small molecule drug candidate discovered through AIDD.
Executed an exclusive license and commercialization agreement with Apollo Therapeutics Group Limited in respect of our product candidate HEC88473.
Through a licensing agreement, we have granted Shenyang Sunshine Pharmaceutical Co., Ltd. exclusive commercialization rights of Clifutinib Besylate in
respect of specific indications in China.

Submitted a listing application to the NMPA in respect of major products, Netanasvir Phosphate Capsules and Encofosbuvir Tablets, which are Category 1 new drugs, and the application was accepted.
The Company was restructured into a joint stock limited company.

Company’s Fingolimod capsules became the first generic drug in China to successfully challenge the patent of a U.S. overseas drug.

Company’s insulin analog insulin glargine injection was approved for marketing by the NMPA.

Introduced Pre-Listing Investors.
The Company's first Class I innovative drug developed in-house, Dongweien (emitasvir phosphate), was approved for listing by the NMPA through the priority review and approval process.

The first innovative drug, Yinfenidone, received clinical trial approval from the U.S. FDA and received FDA’s orphan drug designation in the same year.

Approved by the Ministry of Science and Technology of the PRC to establish a state key laboratory for the R&D of new anti-infective drugs.

The first product in Europe, Azithromycin tablets was approved, which was listed in Germany under its own brand in the same year.

Our Group’s main product, oseltamivir phosphate, received patent authorization from Roche.

The Company established a research institute and began to build an R&D team as well as an independent R&D platform.

The Company was established in Dongguan, Guangdong Province and started to engage in pharmaceutical business.